MenACYW conjugate vaccine

MenACYW conjugate vaccine es un fármaco en desarrollo de Sanofi. Tiene 7 ensayos clínicos registrados, 1 en marcha; lo más avanzado, fase 3.

SNY Sanofi

Sus ensayos

Para qué	Fase	Estado
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China NCT07135986	Fase 3	En marcha, sin reclutar
Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers NCT06284915	Fase 3	Completado
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy NCT05929651	Fase 4	Completado
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US NCT03537508	Fase 3	Completado
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe NCT03547271	Fase 3	Completado
Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children NCT03476135	Fase 3	Completado
Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers NCT03205371	Fase 3	Completado

¿Cuándo se esperan resultados? Está en el calendario, para quien tiene cuenta. Crear una cuenta.

Ensayos del registro público de ClinicalTrials.gov; noticias, de los documentos que la empresa presenta ante la SEC. No son recomendaciones de inversión.